Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...
The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...
Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...
Bob Duggan’s success shows you don’t need a Ph.D., or even a college education, to make money in the complex world of biotech ...
Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...
Monday’s edition of Forbes Daily covers simmering conflict in the Middle East, the GOP’s embrace of cannabis, Adam Neumann’s latest venture in Saudi Arabia and more.
Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...
A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids
STAT's podcast The Readout Loud discusses Summit's cancer immunotherapy, the company's co-CEO, Moderna's spending cuts and ...
Investors were undoubtedly especially glad to see key insiders agree to buy more Summit Therapeutics stock. Together, co-CEOs ...
Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback